Effect of pretreatment with pioglitazone on reperfusion injury in diabetic patients with acute myocardial infarction

Circulation Journal

Volumn 75, Issue 8, 2011, Pages 1968-1974

  Kataoka, Yu ^a   Yagi, Nobuhito ^a   Kokubu, Nobuaki ^a   Kasahara, Yoichiro ^a   Abe, Mitsuru ^a   Otsuka, Yoritaka ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Acute myocardial infarction; Pioglitazone; Reperfusion injury

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; BUFORMIN; CALCIUM CHANNEL BLOCKING AGENT; CREATINE KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; NATEGLINIDE; PIOGLITAZONE; VOGLIBOSE;

ACUTE HEART INFARCTION; AGED; ARTICLE; BARE METAL STENT; CIGARETTE SMOKING; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; FAMILY HISTORY; FEMALE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART MUSCLE BLOOD FLOW; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NO REFLOW PHENOMENON; REPERFUSION INJURY; RISK FACTOR; ST SEGMENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBECTOMY; TREATMENT OUTCOME;

AGED; CREATINE KINASE; DIABETES COMPLICATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; STROKE VOLUME; THIAZOLIDINEDIONES;

EID: 79960792096     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0098     Document Type: Article

References (39)

1. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al; Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003; 24: 28-66.
2. Verma S, Fedak PW, Weisel RD, Butany J, Rao V, Maitland A, et al. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation 2002; 105: 2332-2336.
3. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-1135.
4. Zeymer U, Suryapranata H, Monassier JP, Opolski G, Davies J, Rasmanis G, et al. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction: Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol 2001; 38: 1644-1650.
5. European Study of Prevention of Infarct with Molsidomine (ESPRIM) Group. The ESPRIM trial: Short-term treatment of acute myocardial infarction with molsidomine. Lancet 1994; 344: 91-97.0
6. Wall TC, Califf RM, Blankenship J, Talley JD, Tannenbaum M, Schwaiger M, et al. Intravenous Fluosol in the treatment of acute myocardial infarction: Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial: TAMI 9 Research Group. Circulation 1994; 90: 114-120.
7. Schoonjans K, Auwerx J. Thiazolidinediones: An update. Lancet 2000; 355: 1008-1010.
8. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, et al; GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-1554.
9. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
10. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-86.
11. Takano H, Nagai T, Asakawa M, Toyozaki T, Oka T, Komuro I, et al. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res 2000; 87: 596-602.
12. Ogasawara D, Shite J, Shinke T, Watanabe S, Otake H, Tanino Y, et al. Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus. Circ J 2009; 73: 343-351.
13. Honda T, Kaikita K, Tsujita K, Hayasaki T, Matsukawa M, Fuchigami S, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemiareperfusion injury in mice with metabolic disorders. J Mol Cell Cardiol 2008; 44: 915-926.
14. Ye Y, Hu Z, Lin Y, Zhang C, Perez-Polo JR. Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury. Cardiovasc Res 2010; 87: 535-544.
15. Ito H, Nakano A, Kinoshita M, Matsumori A. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab Invest 2003; 83: 1715-1721.
16. Matetzky S, Novikov M, Gruberg L, Freimark D, Feinberg M, Elian D, et al. The significance of persistent ST elevation versus early resolution of ST segment elevation after primary PTCA. J Am Coll Cardiol 1999; 34: 1932-1938.
17. Iwakura K, Ito H, Kawano S, Shintani Y, Yamamoto K, Kato A, et al. Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J Am Coll Cardiol 2001; 38: 472-477.
18. van't Hof A.W, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: Myocardial blush grade: Zwolle Myocardial Infarction Study Group. Circulation 1998; 97: 2302-2306.
19. Li J, Lang MJ, Mao XB, Tian L, Feng YB. Antiapoptosis and mitochondrial effect of pioglitazone preconditioning in the ischemic/ reperfused heart of rat. Cardiovasc Drugs Ther 2008; 22: 283-291.
20. Yokoyama J, Sutoh N, Higuma T, Horiuchi D, Katoh C, Yokota T, et al. Efficacy and safety of low-dose pioglitazone after primary coronary angioplasty with the use of bare metal stent in patients with acute myocardial infarction and with type 2 diabetes mellitus or impaired glucose tolerance. Heart Vessels 2007; 22: 146-151.
21. Kaneda H, Shiono T, Miyashita Y, Takahashi S, Taketani Y, Domae H, et al. Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation. Heart 2009; 95: 1079-1084.
22. Yasuda S, Shimokawa H. Acute myocardial infarction: The enduring challenge for cardiac protection and survival. Circ J 2009; 73: 2000-2008.
23. Frangogiannis NG. Chemokines in ischemia and reperfusion. Thromb Haemost 2007; 97: 738-747.
24. Kobara M, Sunagawa N, Abe M, Tanaka N, Toba H, Hayashi H, et al. Apoptotic myocytes generate monocyte chemoattractant protein- 1 and mediate macrophage recruitment. J Appl Physiol 2008; 104: 601-609.
25. Sasaki H, Ogawa K, Shimizu M, Mori C, Takatsuka H, Okazaki F, et al. The insulin sensitizer pioglitazone improves the deterioration of ischemic preconditioning in type 2 diabetes mellitus rats. Int Heart J 2007; 48: 623-635.
26. Oswald GA, Smith CC, Betteridge DJ, Yudkin JS. Determinants and importance of stress hyperglycemia in non-diabetic patients with myocardial infarction. BMJ 1986; 293: 917-922.
27. Oswald GA, Smith CC, Delamothe AP, Betteridge DJ, Yudkin JS. Raised concentrations of glucose and adrenaline and increased in vivo platelet activation after myocardial infarction. Br Heart J 1988; 59: 663-671.
28. Kobayashi D, Takamura M, Murai H, Usui S, Ikeda T, Inomata J, et al. Effect of pioglitazone on muscle sympathetic nerve activity in type 2 diabetes mellitus with alpha-glucosidase inhibitor. Auton Neurosci 2010; 158: 86-91.
29. Takagi T, Okura H, Kobayashi Y, Kataoka T, Taguchi H, Toda I, et al. POPPS Investigators: A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). JACC Cardiovasc Interv 2009; 2: 524-531.
30. Marx N, Wöhrle J, Nusser T, Walcher D, Rinker A, Hombach V, et al. Pioglitazone reduces neointima volume after coronary stent implantation: A randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 2005; 112: 2792-2798.
31. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, et al. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 2000; 101: 1311-1318.
32. Igarashi M, Hirata A, Yamaguchi H, Tsuchiya H, Ohnuma H, Tominaga M, et al. Characterization of an inhibitory effect of pioglitazone on balloon-injured vascular smooth muscle cell growth. Metabolism 2001; 50: 955-962.
33. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
34. Nissen SE, Wolski K. Rosiglitazone revisited: An updated metaanalysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010; 170: 1191-1201.
35. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: A teleo-analysis. Diabetes Care 2007; 30: 2148-2153.
36. Rosen CJ. The rosiglitazone story: Lessons from and FAD Advisory Committee meeting. N Eng J Med 2007; 357: 844-846.
37. Lipscombe LL, Gomes T, Lévesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007; 298: 2634-2643.
38. Hsiao FY, Huang WF, Wen YW, Chen PF, Kuo KN, Tsai YW. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: A retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. Drug Safe 2009; 32: 675-690.
39. Hanefeld M, Marx N, Pfützner A, Baurecht W, Lübben G, Karagiannis E, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: The PIOSTAT Study. J Am Coll Cardiol 2007; 49: 290-297.